BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND ABL1, p150, 25, ENSG00000097007, P00519, v-abl, bcr/abl, JTK7, c-ABL, ABL, BCR-ABL AND Clinical Outcome
256 results:

  • 1. Suspected primary bone marrow T-cell lymphoid neoplasia causing paraneoplastic hypercalcemia in 11 dogs (2014-2021).
    Portanova A; Rout ED; Avery AC; Viall AK
    J Am Vet Med Assoc; 2024 Mar; 262(3):1-9. PubMed ID: 37922707
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
    Siegelmann-Danieli N; Neiman V; Bareket-Samish A; Berger R; Peretz A; Alapi H; Tsur E; Patalon T; Beller D; Rimler G; Chodick G; Shohat M
    Prostate; 2024 Jan; 84(1):39-46. PubMed ID: 37842866
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. clinical outcomes of
    Hansen KH; Johansen JS; Urbanska EM; Meldgaard P; Hjorth-Hansen P; Kristiansen C; Stelmach M; Santoni-Rugiu E; Ulhøi MP; Dydensborg AB; Dünweber C; Andersen JL
    Acta Oncol; 2023 Dec; 62(12):1775-1783. PubMed ID: 37815923
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Leukapheresis and Tisagenlecleucel Manufacturing outcomes in Patients Age <3 Years with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Fong D; Tiwari R; Acker C; Clough L; Willert J
    Transplant Cell Ther; 2023 Sep; 29(9):579.e1-579.e10. PubMed ID: 37311511
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome.
    Štach M; Pytlík R; Šmilauerová K; Rychlá J; Mucha M; Musil J; Koladiya A; Nemec M; Petráčková M; Kaštánková I; Pecherková P; Šrámková L; Polgárová K; Trněný M; Lesný P; Vydra J; Otáhal P
    Pathol Oncol Res; 2023; 29():1610914. PubMed ID: 37151356
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Implication of Dynamin-2 (DNM2) Mutations in Adult T-cell Acute Lymphoblastic Leukemia.
    Sobh M; Aref S; Al Agdar M; El Zafrany M; El-Sokkary AMA
    Asian Pac J Cancer Prev; 2023 Apr; 24(4):1257-1264. PubMed ID: 37116148
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study.
    Lazzarotto D; Tanasi I; Vitale A; Piccini M; Dargenio M; Giglio F; Forghieri F; Fracchiolla N; Cerrano M; Todisco E; Papayannidis C; Leoncin M; Defina M; Guolo F; Pasciolla C; Delia M; Chiusolo P; Mulè A; Candoni A; Bonifacio M; Pizzolo G; Foà R
    Ann Hematol; 2023 May; 102(5):1099-1109. PubMed ID: 36959485
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Association of Minimal Residual Disease by a Single-Tube 8-Color Flow Cytometric Analysis With clinical outcome in Adult B-Cell Acute Lymphoblastic Leukemia: A Real-World Study Based on 486 Patients.
    Liao H; Jiang N; Yang Y; Zhang X; Chen J; Lai H; Zheng Q
    Arch Pathol Lab Med; 2023 Oct; 147(10):1186-1195. PubMed ID: 36508349
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients.
    Li D; Jiang H; Jin F; Pan L; Xie Y; Zhang L; Li C
    Genes Genomics; 2023 Jan; 45(1):93-102. PubMed ID: 36445572
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Lack of FLT3-ITD in Tunisian childhood acute lymphoblastic leukemia.
    Frikha R; Abdellaoui N; Kassar O; Rebai T
    Afr Health Sci; 2022 Jun; 22(2):318-322. PubMed ID: 36407352
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.
    Kiamanesh Z; Ayati N; Sadeghi R; Hawkes E; Lee ST; Scott AM
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4661-4676. PubMed ID: 35932329
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement.
    Bomken S; Enshaei A; Schwalbe EC; Mikulasova A; Dai Y; Zaka M; Fung KTM; Bashton M; Lim H; Jones L; Karataraki N; Winterman E; Ashby C; Attarbaschi A; Bertrand Y; Bradtke J; Buldini B; Burke GAA; Cazzaniga G; Gohring G; De Groot-Kruseman HA; Haferlach C; Nigro LL; Parihar M; Plesa A; Seaford E; Sonneveld E; Strehl S; Van der Velden VHJ; Rand V; Hunger SP; Harrison CJ; Bacon CM; Van Delft FW; Loh ML; Moppett J; Vormoor J; Walker BA; Moorman AV; Russell LJ
    Haematologica; 2023 Mar; 108(3):717-731. PubMed ID: 35484682
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [Cerebrospinal Fluid β2-Microglobulin for Prognostic Evaluation of Patients with Central Nervous System Infiltration in Acute Lymphoblastic Leukemia].
    Yao ML; Chen TM; Li P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):113-118. PubMed ID: 35123612
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. RUNX1 transactivates bcr-abl1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.
    Masuda T; Maeda S; Shimada S; Sakuramoto N; Morita K; Koyama A; Suzuki K; Mitsuda Y; Matsuo H; Kubota H; Kato I; Tanaka K; Takita J; Hirata M; Kataoka TR; Nakahata T; Adachi S; Hirai H; Mizuta S; Naka K; Imai Y; Kimura S; Sugiyama H; Kamikubo Y
    Cancer Sci; 2022 Feb; 113(2):529-539. PubMed ID: 34902205
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Whole-body MRI radiomics model to predict relapsed/refractory Hodgkin lymphoma: A preliminary study.
    Albano D; Cuocolo R; Patti C; Ugga L; Chianca V; Tarantino V; Faraone R; Albano S; Micci G; Costa A; Paratore R; Ficola U; Lagalla R; Midiri M; Galia M
    Magn Reson Imaging; 2022 Feb; 86():55-60. PubMed ID: 34808304
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [Expression and Prognostic Value of Metabolism-related Genes in Pediatric Acute Lymphoblastic Leukemia].
    Zhang H; Chen J; Ma HZ; Zhao L; Xi YM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1375-1379. PubMed ID: 34627413
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
    Dodero A; Guidetti A; Marino F; Tucci A; Barretta F; Re A; Balzarotti M; Carniti C; Monfrini C; Chiappella A; Cabras A; Facchetti F; Pennisi M; Rahal D; Monti V; Devizzi L; Miceli R; Cocito F; Farina L; Ricci F; Rossi G; Carlo-Stella C; Corradini P
    Haematologica; 2022 May; 107(5):1153-1162. PubMed ID: 34289655
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients.
    Rasekh EO; Osman R; Ibraheem D; Madney Y; Radwan E; Gameel A; Abdelhafiz A; Kamel A; Elfishawi S
    Ann Hematol; 2021 Mar; 100(3):699-707. PubMed ID: 33230570
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia.
    Lanza F; Maffini E; Saraceni F; Massari E; Rondoni M; Daghia G; Olivieri A; Cerchione C; Martinelli G
    Minerva Med; 2020 Oct; 111(5):478-490. PubMed ID: 32955830
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.
    Saberi Hosnijeh F; van der Straten L; Kater AP; van Oers MHJ; Posthuma WFM; Chamuleau MED; Bellido M; Doorduijn JK; van Gelder M; Hoogendoorn M; de Boer F; Te Raa GD; Kerst JM; Marijt EWA; Raymakers RAP; Koene HR; Schaafsma MR; Dobber JA; Tonino SH; Kersting SS; Langerak AW; Levin MD
    Exp Hematol; 2020 Sep; 89():55-60.e6. PubMed ID: 32781097
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 13.